Shigeru Kawabata

2.8k citations

46 papers · 2.3k indexed · 1 hit paper · h-index 18

Oncology top 2%
- Lung Cancer Research Studies 8
- Drug Transport and Resistance Mechanisms 6
- Peptidase Inhibition and Analysis 3
Virology top 5%
Molecular Biology top 10%
- Cancer therapeutics and mechanisms 8
- PI3K/AKT/mTOR signaling in cancer 5
- Biochemical and Molecular Research 3
Cancer Research top 10%
Immunology top 10%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 7
Infectious Diseases
- HIV/AIDS drug development and treatment 4

Co-authors: Phillip A. Dennis Joell J. Gills Regan M. Memmott Stephen D. Fox Hiroshi Soda Jose R. Mercado Colleen R. Maier Willie Wilson
Cited by: Oncology Virology Molecular Biology
Partner nations: Japan United States Malaysia

In The Last Decade

Shigeru Kawabata

43 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

Peers

Countries citing papers authored by Shigeru Kawabata

Since Specialization

Citations

This map shows the geographic impact of Shigeru Kawabata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeru Kawabata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeru Kawabata more than expected).

Fields of papers citing papers by Shigeru Kawabata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigeru Kawabata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeru Kawabata. The network helps show where Shigeru Kawabata may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shigeru Kawabata, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shigeru Kawabata Line = papers co-authored together Shigeru Kawabata links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer Kenjiro Tsuruoka,Yosuke Tamura,Yosuke Shimazu,Masahiro Arai,SHO MITSUYA,Tomoya Funamoto,Hiroyuki Tsuji,Ninso Matsunaga,Takahiko Nakamura,Soichiro Ikeda,Shigeru Kawabata,Akihisa Imagawa,Yasuhito Fujisaka	2024	0
2	A case of renomedullary interstitial cell tumor: Radiologic-pathologic correlation Kiyohito Yamamoto,Shigeru Kawabata,Yoshitaka Kurisu,Teruo Inamoto,Kazuhiro Yamamoto,Keigo Osuga	2023	0
3	Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia Yoon Soo Chang,Joell J. Gills,Shigeru Kawabata,Masahiro Onozawa,Giusy Della Gatta,Adolfo A. Ferrando,Peter D. Aplan,Phillip A. Dennis	2023	5
4	Breast neuroendocrine tumor arising in the axilla of a man: a case report Kosei Kimura,Shigeru Kawabata,Hiroyo Oku,Ayana Ikari,Tomo Tominaga,Saki Takai,Junna Sakane,M. Tanaka,Chinatsu Aoki,Monika Ota,Erika Minami,Yoshinobu Hirose,Sang‐Woong Lee,Mitsuhiko Iwamoto	2022	1
5	Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors Shigeru Kawabata,Nick Connis,Joell J. Gills,Christine L. Hann,Phillip A. Dennis	2021	5
6	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer Takefumi Komiya,Regan M. Memmott,Gideon M. Blumenthal,(unknown),Marc Ballas,Roopa De Chowdhury,Guinevere Chun,Cody J. Peer,William D. Figg,David J. Liewehr,Seth M. Steinberg,Giuseppe Giaccone,Éva Szabó,Shigeru Kawabata,Junji Tsurutani,Arun Rajan,Phillip A. Dennis	2019	12
7	Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancerbreakdown → Kristin J. Lastwika,Willie Wilson,Qing Kay Li,Jeffrey W. Norris,Haiying Xu,Sharon R. Ghazarian,Hiroshi Kitagawa,Shigeru Kawabata,Janis M. Taube,Sheng Yao,Linda N. Liu,Joell J. Gills,Phillip A. Dennis	2015	643
8	Impact of HIV on lung tumorigenesis in an animal model Shigeru Kawabata,Alonso Heredia,Joell J. Gills,Robert Redfield,Phillip A. Dennis,Joseph Bryant	2015	6
9	SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines İrem Doğan,Shigeru Kawabata,Emily Anne Smith Bergbower,Joell J. Gills,Abdullah Ekmekçi,Willie Wilson,Charles M. Rudin,Phillip A. Dennis	2014	25
10	Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells Shigeru Kawabata,Joell J. Gills,J R Mercado-Matos,Jaclyn LoPiccolo,Wyndham H. Wilson,M. Christine Hollander,Phillip A. Dennis	2012	59
11	Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis Regan M. Memmott,Jose R. Mercado,Colleen R. Maier,Shigeru Kawabata,Stephen D. Fox,Phillip A. Dennis	2010	345
12	Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo Joell J. Gills,Jaclyn LoPiccolo,Junji Tsurutani,Robert H. Shoemaker,Carolyn J.M. Best,Mones Abu‐Asab,Jennifer Borojerdi,Noel A. Warfel,Erin R. Gardner,Matthew Danish,M. Christine Hollander,Shigeru Kawabata,Maria Tsokos,William D. Figg,Patricia S. Steeg,Phillip A. Dennis	2007	264
13	Interruption of p16 gene expression in adult T‐cell leukaemia/lymphoma: clinical correlation Yumi Takasaki,Yasuaki Yamada,Kazuyuki Sugahara,Tomomi Hayashi,Natsuko Dateki,Hitomi Harasawa,Shigeru Kawabata,Hiroshi Soda,Shu‐ichi Ikeda,Masao Tomonaga,Shimeru Kamihira	2003	16
14	Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer Masaaki Oka,Minoru Fukuda,Mutsuo Kuba,Masao Ichiki,Toru Rikimaru,Hiroshi Soda,Junji Tsurutani,Yoichi Nakamura,Shigeru Kawabata,Katsumi Nakatomi,Fumihiko Narasaki,Seiji Nagashima,Hiroshi Takatani,Akitoshi Kinoshita,S Kohno	2002	18
15	Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer Mikio Oka,Minoru Fukuda,Seiji Nagashima,Masaaki Fukuda,Akitoshi Kinoshita,Hiroshi Soda,Seiji Doi,Fumihiko Narasaki,Mitsuhiro Suenaga,Hiroshi Takatani,Yoichi Nakamura,Shigeru Kawabata,Junji Tsurutani,Tetsuro Kanda,Shigeru Kohno	2001	11
16	Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer Cells Katsumi Nakatomi,Megumi Yoshikawa,Mikio Oka,Yoji Ikegami,Shinya Hayasaka,Kazumi Sano,Ken Shiozawa,Shigeru Kawabata,Hiroshi Soda,Toshihisa Ishikawa,Shinzo Tanabe,Shigeru Kohno	2001	161
17	Histone deacetylase inhibitors suppress telomerase reverse transcriptase mrna expression in prostate cancer cells Mitsuhiro Suenaga,Hiroshi Soda,Mikio Oka,Akihiko Yamaguchi,Katsumi Nakatomi,Ken Shiozawa,Shigeru Kawabata,Takashi Kasai,Yasuaki Yamada,Shimeru Kamihira,Chuwa Tei,Shigeru Kohno	2001	67
18	Birth Cohort Effects on Incidence of Lung Cancers: A Population‐based Study in Nagasaki, Japan Hiroshi Soda,Mikio Oka,Midori Soda,Katsumi Nakatomi,Shigeru Kawabata,Mitsuhiro Suenaga,T. Kasai,Yasuaki Yamada,Shimeru Kamihira,Shigeru Kohno	2000	7
19	Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells. Keigo Ikeda,Makoto Oka,Fumihiko Narasaki,M. Fukuda,Takahiko Nakamura,Seiji Nagashima,Kenji Terashi,S Sato,Shigeru Kawabata,Yuichi Mizuta,Hiroshi Soda,S. Kohno	1998	13
20	A Leukotriene Receptor Antagonist, ONO-1078, Modulates Drug Sensitivity and Leukotriene C4Efflux in Lung Cancer Cells Expressing Multidrug Resistance Protein Reiji Nakano,Mikio Oka,Takashi Nakamura,Minoru Fukuda,Shigeru Kawabata,Kenji Terashi,Kazuhiro Tsukamoto,Yuji Noguchi,Hiroshi Soda,Shigeru Kohno	1998	22

About Shigeru Kawabata

Shigeru Kawabata is a scholar working on Microbiology, Oncology and Virology, having authored 46 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (8 papers), Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers), Drug Transport and Resistance Mechanisms (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), HIV/AIDS drug development and treatment (4 papers), Biochemical and Molecular Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Oncology (1.3k citations), Virology (87 citations) and Molecular Biology (1.2k citations). Shigeru Kawabata has collaborated with scholars based in Japan, United States and Malaysia. Frequent co-authors include Phillip A. Dennis, Joell J. Gills, Regan M. Memmott, Stephen D. Fox, Hiroshi Soda, Jose R. Mercado, Colleen R. Maier, Willie Wilson, Katsumi Nakatomi and Sheng Yao.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact